None of these existing scales have been scientifically validated. You likely see information collected via diaries that might contribute to side-effect profiles for various treatments being investigated.

The problem we are addressing is the lack of validated clinical endpoints for trials of dyskinesias therapeutics themselves. Without the validated end points, the regulatory pathway is unknown.

Our effort was undertaken at the urging of several companies with potential compounds that could improve our ability to treat dyskinesias (which of course would be huge!).

d